Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

BACKGROUND: Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609503/
https://www.ncbi.nlm.nih.gov/pubmed/27402060
http://dx.doi.org/10.1016/j.eururo.2016.06.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609503/
https://www.ncbi.nlm.nih.gov/pubmed/27402060
http://dx.doi.org/10.1016/j.eururo.2016.06.033

Ejemplares similares